Oncothyreon Inc (NASDAQ:ONTY)

2.51
Delayed Data
As of May 21
 +0.09 / +3.72%
Today’s Change
1.41
Today|||52-Week Range
3.60
+32.11%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$247.6M

Company Description

Oncothyreon, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Its current clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. The company was founded on September 7, 2007 and is headquartered in Seattle, WA.

Contact Information

Oncothyreon, Inc.
2601 4th Avenue
Seattle Washington 98121
P:(206) 801-2100
Investor Relations:

Employees

Shareholders

Other institutional45.15%
Mutual fund holders18.13%
Individual stakeholders14.88%

Top Executives

Robert L. KirkmanPresident, Chief Executive Officer & Director
Gary W. ChristiansonChief Operating Officer
Julia Marie EastlandCFO, Secretary & VP-Corporate Development
Scott Robert PetersonChief Scientific Officer
Diana F. HausmanChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account